DRD2 and neoplasm: In preclinical models, the nanocarrier selectively localized to the resection cavity due to the platelets’ innate injury-homing behavior, while the PDA surface enabled GSC targeting via dopamine-D2-receptor-mediated recognition, leading to effective inhibition of tumor recurrence [490].